Our History

WuXi PharmaTech was founded to support innovators in discovering, developing and commercializing new medicines and healthcare products for patients

Launched synthetic chemistry services

Began manufacturing process development services

Initiated manufacturing services for research and development

Started bio-analytical services

Began offering toxicology and formulation services Listed on the New York Stock Exchange

Acquired AppTec Laboratory Services, after which the company was renamed WuXi AppTec

Acquired Medkey, expanding to clinical development and registration services First annual WuXi Global Forum held in San Francisco alongside the J.P. Morgan Healthcare Conference

Acquired XenoBiotic Laboratories, adding to the company’s research capabilities

Expanded medical device testing services Delisted from the New York Stock Exchange

Acquired CRELUX, enhancing WuXi AppTec's structure-based drug discovery capabilities

Acquired HD Biosciences, strengthening biology R&D capacity and capability Acquired ResearchPoint Global, expanding U.S. clinical research capabilities

Listed on Shanghai Exchange (603259.SH)

Listed on Hong Kong Exchange (2359.HK)

Acquired Pharmapace, to enhance biometrics services for clinical development

Purchased Bristol Myers Squibb manufacturing facility in Couvet, Switzerland

Opening of the first high potency oral drug product manufacturing facility, expanding integrated drug product R&D and manufacturing services

Expanded peptide manufacturing capacity

Expanded Munich site, Germany, housing multiple capabilities under one roof in Europe